Format

Send to

Choose Destination
Antiviral Res. 2016 Apr;128:7-19. doi: 10.1016/j.antiviral.2016.01.002. Epub 2016 Jan 19.

The development of therapeutic antibodies against dengue virus.

Author information

1
Programme in Emerging Infectious Diseases, Duke-NUS Medical School, 8 College Road, Singapore, 169857; Centre for BioImaging Sciences, National University of Singapore, 14 Science Drive 4, Singapore, 117557. Electronic address: gfibriansah@duke-nus.edu.sg.
2
Programme in Emerging Infectious Diseases, Duke-NUS Medical School, 8 College Road, Singapore, 169857; Centre for BioImaging Sciences, National University of Singapore, 14 Science Drive 4, Singapore, 117557. Electronic address: sheemei.lok@duke-nus.edu.sg.

Abstract

Dengue virus, a positive-sense RNA virus, is one of the major human pathogens transmitted by mosquitoes. However, no fully effective licensed dengue vaccines or therapeutics are currently available. Several potent neutralizing antibodies against DENV have been isolated from mice and humans, and the characterization of their properties by biochemical and biophysical methods have revealed important insights for development of therapeutic antibodies. In this review, we summarize recently reported antibody-antigen complex structures, their likely neutralization mechanisms and enhancement propensities, as well as their prophylactic and therapeutic capabilities in mouse models. This article forms part of a symposium on flavivirus drug discovery in the journal Antiviral Research.

KEYWORDS:

Antibody; Dengue virus; Flavivirus; Neutralization mechanism; Therapeutic antibodies

PMID:
26794397
DOI:
10.1016/j.antiviral.2016.01.002
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center